Literature DB >> 20802526

K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.

B Alvarez-Moya1, C López-Alcalá, M Drosten, O Bachs, N Agell.   

Abstract

Fine tuning of Ras activity is widely known as a mechanism to induce different cellular responses. Recently, we have shown that calmodulin (CaM) binds to K-Ras and that K-Ras phosphorylation inhibits its interaction with CaM. In this study we report that CaM inhibits K-Ras phosphorylation at Ser181 by protein kinase C (PKC) in vivo, and this is a mechanism to modulate K-Ras activity and signaling. Although CaM inhibition increased the activation of endogenous K-Ras, PKC inhibition decreased its activation status. We demonstrate that K-Ras phosphorylation decreased susceptibility to p120GAP activity. Accordingly, we also observed that non-phosphorylable K-Ras mutant exhibits a less sustained activation profile and do not efficiently activate AKT at low growth factor doses compared with wild-type K-Ras. It is interesting that the physiological responses induced by K-Ras are affected by this phosphorylation; when K-Ras cannot be phosphorylated it exhibits a remarkably decreased ability to stimulate proliferation in non-saturated serum conditions. Finally, we demonstrate that phosphorylation also regulates oncogenic K-Ras functions, as focus formation capacity, mobility and apoptosis resistance upon adriamycin treatment of cells expressing oncogenic K-Ras that cannot be phosphorylated are highly compromised. Moreover, at low serum concentration proliferation and survival is practically inhibited when cells cannot phosphorylate oncogenic K-Ras. In this condition, K-Ras phosphorylation is essential to ensure a proper activation of mitogen-activated protein kinase and PI3K/AKT pathways. In summary, our findings suggest that the interplay between CaM interaction and PKC phosphorylation is essential to regulate non-oncogenic and oncogenic K-Ras activity and functionality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802526     DOI: 10.1038/onc.2010.298

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

Review 1.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

2.  Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.

Authors:  Imanol Arozarena; Fernando Calvo; Piero Crespo
Journal:  Genes Cancer       Date:  2011-03

Review 3.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 4.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

Review 5.  Annexin A6-A multifunctional scaffold in cell motility.

Authors:  Thomas Grewal; Monira Hoque; James R W Conway; Meritxell Reverter; Mohamed Wahba; Syed S Beevi; Paul Timpson; Carlos Enrich; Carles Rentero
Journal:  Cell Adh Migr       Date:  2017-01-06       Impact factor: 3.405

6.  Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane.

Authors:  Bindu Lakshman; Simon Messing; Eva M Schmid; Jeffrey D Clogston; William K Gillette; Dominic Esposito; Bailey Kessing; Daniel A Fletcher; Dwight V Nissley; Frank McCormick; Andrew G Stephen; Frantz L Jean-Francois
Journal:  J Biol Chem       Date:  2018-12-17       Impact factor: 5.157

Review 7.  Intrinsic protein disorder in oncogenic KRAS signaling.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai; Tsung-Jen Liao; Shuai Li; David Fushman; Jian Zhang
Journal:  Cell Mol Life Sci       Date:  2017-06-08       Impact factor: 9.261

8.  Differences in the Phosphorylation-Dependent Regulation of Prenylation of Rap1A and Rap1B.

Authors:  Jessica M Wilson; Jeremy W Prokop; Ellen Lorimer; Elizabeth Ntantie; Carol L Williams
Journal:  J Mol Biol       Date:  2016-10-17       Impact factor: 5.469

Review 9.  Calmodulin and PI3K Signaling in KRAS Cancers.

Authors:  Ruth Nussinov; Guanqiao Wang; Chung-Jung Tsai; Hyunbum Jang; Shaoyong Lu; Avik Banerjee; Jian Zhang; Vadim Gaponenko
Journal:  Trends Cancer       Date:  2017-02-18

10.  The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Lu Zhou; David A Hilton; Magdalena Barczyk; Clemens Oliver Hanemann
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.